Read by QxMD icon Read

allogeneic hematopoietic stem cell transplantation

Seyed Ahmad Hoseinian, Davood Jafari, Mehdi Mahmoodi, Kamran Alimoghaddam, Mohammadreza Ostadali, Azita Talebzadeh Bonakdar, Arron Munggela Foma, Mir Saeed Yekaninejad, Ali Akbar Amirzargar
Background/aim: After allogeneic hematopoietic stem cell transplantation (allo-HSCT), donor natural killer (NK) cells trigger alloreactions against potential recipient cells by their killer immunoglobulin-like receptors (KIRs). This study investigated whether KIR/HLA genotypes and KIR haplotypes of donors and recipients exhibit a critical function in the prevalence of acute graft-versus-host disease (aGVHD) and persistence of the graft after HLA-identical sibling allo-HSCT for patients with hematological malignancies...
August 16, 2018: Turkish Journal of Medical Sciences
Daria Bortolotti, Filippo Rossignoli, Antonella Rotola, Diana Campioni, Rosario Cultrera, Giulia Grisendi, Massimo Dominici, Roberta Rizzo
OBJECTIVES: Mesenchymal stromal/stem cells have immunosuppressive functions. Our previous results demonstrated that one of the players of this immunomodulation can be ascribed to the Human Leukocyte Antigen-G. HLA-G, a non classical HLA class I antigen, is involved in immune tolerance during pregnancy, organ transplantation, autoimmune and inflammatory diseases. In this study we wanted to verify whether human endometrial decidual tissue derived (EDT)-MSC could express HLA-G. Additionally we assessed the permissivity to Human Herpesvirus infections, using HSV-1 as a model, and the possible effect on EDT-MSC immunosuppressive functions towards peripheral blood mononuclear cell (PBMC) proliferation...
August 14, 2018: Human Immunology
Fedja Farowski, Gregor Els, Anastasia Tsakmaklis, Paul G Higgins, Christian R Kahlert, Christoph K Stein-Thoeringer, Johanna S Bobardt, Katja Dettmer-Wilde, Peter J Oefner, Jörg Janne Vehreschild, Maria J G T Vehreschild
OBJECTIVES: After allogeneic hematopoietic stem cell transplantation (allo-HCT), urinary levels of 3-indoxyl sulfate (3-IS) correlate with the relative abundance of bacteria from the class Clostridia (RAC), and antibiotic treatment is considered the major determinant of this outcome. A high RAC has been associated with favorable outcome after allo-HCT and protection from Clostridium difficile infection (CDI). We assessed correlations between alpha diversity, RAC and urinary 3-IS levels in a non-allo-HCT clinical cohort of antibiotic treated patients to further explore 3-IS as a biomarker of reduced diversity and predisposition to CDI...
August 17, 2018: Gut Microbes
Daniel Kerr Ii, Lubomir Sokol
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematopoietic malignancy that contributes to < 1% of all hematologic malignancies. Before the introduction of various targeted agents, the therapeutic approach was based on regimens used for acute lymphoblastic or myeloid leukemia and non-Hodgkin's lymphoma (e.g., hyperCVAD and CHOP-based regimens) followed by allogeneic stem cell transplantation for eligible patients. Given that this disease primarily affects older patients, there is a significant barrier to using these highly toxic regimens, even though these regimens are usually associated with the most durable response...
August 17, 2018: Expert Opinion on Investigational Drugs
Ayako Kamiunten, Masaaki Sekine, Takuro Kameda, Keiichi Akizuki, Yuki Tahira, Kotaro Shide, Haruko Shimoda, Koji Kato, Tomonori Hidaka, Yoko Kubuki, Kazuya Shimoda
Adult T cell leukemia/lymphoma (ATL) is an aggressive peripheral T cell neoplasm, and the outcome of patients with ATL after chemotherapy is poor. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a curative treatment modality for ATL, and 4 factors, namely age > 50 years, male recipient, lack of complete remission at transplantation, and transplantation of cord blood, were previously shown to be associated with poor survival. We retrospectively analyzed the outcome of 21 patients with ATL who had undergone allo-HSCT at our hospital during a 3-year period...
August 16, 2018: Hematological Oncology
E A Komech, I V Zvyagin, M V Pogorelyy, I Z Mamedov, D A Fedorenko, Y B Lebedev
Autologous hematopoietic stem cell transplantation (HSCT), a safer type of HSCT than allogeneic HSCT, is a promising therapy for patients with severe autoimmune diseases (ADs). Despite the long history of medical practice, structural changes in the adaptive immune system as a result of autologous HSCT in patients with various types of ADs remain poorly understood. In this study, we used high-throughput sequencing to investigate the structural changes in the peripheral blood T-cell repertoire in adult patients with ankylosing spondylitis (AS) during two years after autologous HSCT...
April 2018: Acta Naturae
Jing Jing Liu, Li Meng
The 8p11 myeloproliferative syndrome (EMS), a rare myeloproliferative disease, generally progresses rapidly and is characterized by chromosomal translocations of the fibroblast growth factor receptor 1 (FGFR1) gene. The FGFR1 gene is located at chromosome 8p11 and may fuse with distinct partner genes. The breakpoint cluster region gene located at chromosome 22 is one of these partner genes. The patients' clinical phenotype is primarily dependant on the partner gene that translocates with FGFR1. Of all the available examinations, determination of the chromosome karyotype is most essential for the diagnosis of EMS...
August 2018: Experimental and Therapeutic Medicine
Gursel Gunes, Hakan Goker, Haluk Demiroglu, Umit Yavuz Malkan, Yahya Buyukasik
The aim of this study was to evaluate extramedullary (EM) relapses and its features in an allogeneic hematopoietic stem cell transplantation (alloHSCT) cohort, which consisted of patients with acute leukemia and advanced-phase chronic myeloid leukemia. One hundred and twenty-eight alloHSCT patients transplanted between the years 2001 and 2014 were analyzed. EM relapses observed in acute lymphoblastic leukemia (ALL) were more frequent than that of in acute myeloid leukemia (AML) and CML, although calculation of cumulative risk incidence, BM relapse, EM relapse, and non-relapse mortality were considered as competing risks of each other...
August 16, 2018: Bone Marrow Transplantation
Monica M Rivera-Franco, Eucario León-Rodríguez, Isabel K Lastra-German, Andrea A Mendoza-Farias
Few authors have reported a decreased frequency of acute graft-versus-host disease (aGVHD) using statins, as these medications have anti-inflammatory effects, however, to date, the direct association between high cholesterol and GVHD has not been reported. The aim of his study was to investigate the association of recipient and donor hypercholesterolemia with the incidence of aGVHD. A retrospective analysis was performed identifying allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients and donors at the National Institute of Medical Sciences and Nutrition in Mexico City between May 1999 and August 2017...
July 30, 2018: Leukemia Research
Jieyun Xia, Haiying Sun, Zhiling Yan, Feng Zhu, Kai Zhao, Kailin Xu
Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL) complicated by bone marrow necrosis (BMN) and acute renal insufficiency (ARI) is rare in clinical practice. The aim of the present study was to summarize the clinical characteristics and treatment methods of a case of Ph+ ALL complicated by BMN and ARI. A 23-year-old male patient presented with pyrexia and a 2-month history of bone pain, and was diagnosed with Ph+ ALL complicated with BMN and ARI on peripheral blood tests, blood biochemistry tests, BM smear and fluorescence in situ hybridization...
September 2018: Molecular and Clinical Oncology
Di Yu, Ya-Hui Han, Chen-Yuan Hu, Bin Zhang, Huan-Xin Zhang, Hu-Jun Li, Kun-Ming Qi, Jiang Cao, Zhen-Yu Li, Zhi-Ling Yan, Kai-Lin Xu
OBJECTIVE: To analyze the risk factors and prognosis of hepatic chronic GVHD after allogeneic hematopoietic stem cell transplantation (allo-HSCT). METHODS: The clinical data of 147 patients undergoing allo-HSCT from January 2013 to December 2016 were analyzed, the correlation between recipient age and sex, disease state, matched degree of HLA, donor sex, stem cell sources, ATG in GVHD prophylaxis, liver dysfunction during conditioning period, pre-transplant HBsAg, prior aGVHD and hepatic cGVHD were studied, and the correlation between hepatic cGVHD and prognosis were analysed...
August 2018: Zhongguo Shi Yan Xue Ye Xue za Zhi
Lan-Lan Deng, Kun-Yin Qiu, Xiong-Yu Liao, Yi-Wen Liang, Ke Huang, Yang Li, Hong-Gui Xu, Jian-Pei Fang, Dun-Hua Zhou
OBJECTIVE: To prospectively study the correlation BKV with the occurrence and development of late onset hemorrhagic cystitis (LOHC) after allogeneic hematopoietic stem cell transplantation(allo-HSCT). METHODS: The clinical data of a total of 276 patients with allo-HSCT in our department between January 1998 and March 2016 were analyzed ratrospectvely. Quantitative Real-time PCR assay was used to prospectively monitor the BKV DNA load of the urine and plasma for 23 patients accepting allo-HSCT from August 2015 to March 2016...
August 2018: Zhongguo Shi Yan Xue Ye Xue za Zhi
Juan Li, Zhi-Biao Zhang, Zheng-Rong Liu, Mei Yang, Yan-Xia Nie, Meng-Meng Wu
OBJECTIVE: To explore the factors influencing total complete remission (CR), recurrence, disease-free survival (DFS) rate and overall survival (OS) rate in adults with Philadelphia (Ph) chromosome negative acute lymphoblastic leukemia (ALL) and the effect of subsequent allogeneic hematopoietic stem cell transplantation (allo-HSCT) on prognosis. METHODS: The clinical data of 87 adult patients with Ph negative ALL were retrospectively analyzed, the CHOP regimen plus L-asparaginase (L-Asp) was used for the induction therapy, and the CHOP+ modified Hyper-CVAD or methotrexate was set up as the consolidation chemotherapy regimen...
August 2018: Zhongguo Shi Yan Xue Ye Xue za Zhi
Allison Barz Leahy, Caitlin W Elgarten, Stephan A Grupp, Shannon L Maude, David T Teachey
Cure rates for pediatric and young adult patients with refractory or recurrently relapsed acute lymphoblastic leukemia are dismal. Survival from time of relapse is typically measured in weeks to months, and standard chemotherapy and currently approved targeted therapy achieve remission in less than a third of affected patients. To date, the only definitive curative therapy has been allogeneic hematopoietic stem cell transplant (HSCT). Advances in immunotherapy, with the introduction of chimeric antigen receptor T cell therapies and the development of tisagenlecleucel, have changed the landscape...
August 15, 2018: Expert Review of Anticancer Therapy
Sarah Kraft, Noémie Bollinger, Benjamin Bodenmann, Dominik Heim, Christoph Bucher, Claudia Lengerke, Martina Kleber, Dimitrios A Tsakiris, Jakob Passweg, Alexandar Tzankov, Michael Medinger
Transplant-associated thrombotic microangiopathy (TA-TMA) remains a major complication of allogeneic hematopoietic stem cell transplantation (allo-HSCT). We hypothesized that TA-TMA correlates with steroid-refractory acute graft-vs.-host disease (aGvHD) and assessed 660 patients suffering from either AML n = 248, ALL n = 79, CML n = 23, CLL n = 36, lymphoma/myeloma n = 127, MDS/MPN n = 124 or bone marrow failure n = 22, who met the study inclusion criteria and had undergone myeloablative (78%) and non-myeloablative (22%) allo-HSCT between 2006 and 2016...
August 14, 2018: Bone Marrow Transplantation
Samantha M Jaglowski, Bruce R Blazar
Allogeneic hematopoietic stem cell transplantation (allo-SCT) is potentially curative for a number of hematologic conditions, both malignant and nonmalignant. However, its success can be limited by the development of acute and chronic graft-versus-host disease (GVHD). Chronic GVHD (cGVHD) is the most common long-term complication following allo-SCT, and patients who develop this condition have significantly higher morbidity and mortality and significantly lower quality of life than patients who do not. Until recently, there were no US Food and Drug Administration (FDA)-approved therapies for cGVHD treatment...
August 14, 2018: Blood Advances
Sung-Soo Park, Young-Woo Jeon, Gi June Min, Silvia Park, Seung-Ah Yahng, Jae-Ho Yoon, Seung-Hwan Shin, Sung-Eun Lee, Byung-Sik Cho, Ki-Seong Eom, Seok Lee, Hee-Je Kim, Chang-Ki Min, Seok-Goo Cho, Jong Wook Lee, Yoo-Jin Kim
Graft-versus-host disease-free, relapse-free survival (GRFS) is a composite endpoint that measures survival free of relapse or significant morbidity following allogeneic hematopoietic stem cell transplantation (HSCT). Consecutive 324 adult patients who received HSCT with fluarabine and busulfan based conditioning for myelodysplastic syndrome (MDS) or secondary acute myeloid leukemia evolved from MDS were retrospectively analyzed. 1-year and 3-year GRFS rates were 47.8% and 34.5%, respectively. Three fixed factors (circulating blast >3%, high cytogenetic risk, and high comorbidity index) and two factors (which is) modifiable by clinicians [myeloablative conditioning and low-dose (<7...
August 10, 2018: Biology of Blood and Marrow Transplantation
Jianwei Zheng, Brian Taylor, Xiao Chen
Vitamin A is an essential micronutrient that participates in a wide range of biological processes. Retinoic acid (RA) is an active metabolite of vitamin A that functions as an immune regulator. Graft-versus-host disease (GVHD) is a major complication of allogeneic hematopoietic stem cell transplantation (HSCT). It is characterized by extensive inflammation arising from an alloimmune response involving various host and donor immune cells. Since vitamin A affects different immune cell lineages and regulates an array of immune responses, vitamin A, and more specifically retinoic acid, is likely to influence the incidence and/or severity of GVHD...
2018: Journal of Immunology Research and Therapy
Chien-Ting Chen, Jyh-Pyng Gau, Jing-Hwang Liu, Tzeon-Jye Chiou, Liang-Tsai Hsiao, Yao-Chung Liu
BACKGROUND: Acute lymphoblastic leukemia (ALL) remains one of the most difficult-to-cure hematological malignancies. Allogeneic hematopoietic stem cell transplantation (HSCT) provides curative potential but a substantial proportion of patients eventually will relapse. It is unknown if there are any modifiable factors exists that could improve survival or predict relapse immediately after HSCT is unknown. The aim of this study was to explore whether achieving early (<30 days) full donor chimerism (FDC) could predict disease relapse after allogeneic HSCT in ALL patients...
August 9, 2018: Journal of the Chinese Medical Association: JCMA
Chetasi Talati, David Sallman, Alan F List
Myelodysplastic syndrome (MDS) with deletion 5q [del(5q)] is a distinct clinical and pathologic disease subset that is exquisitely sensitive to lenalidomide for the treatment of red blood cell transfusion-dependent anemia. Lenalidomide resistance, including primary resistance, occurs by clonal evolution, which is frequently attributable to the presence of somatic mutations in the DNA-binding domain of the TP53 gene. The treatment options after development of resistance to lenalidomide are limited and consist of hypomethylating agents, clinical trials, and allogeneic hematopoietic stem cell transplantation...
July 30, 2018: Clinical Lymphoma, Myeloma & Leukemia
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"